Navigation Links
AMDL, Inc. Announces First Quarter 2009 Financial Results
Date:5/15/2009

that for accounting, legal, investor relations, and financial advisory and independent director services.

Cash Position & Accounts Receivables

As of May 15th, 2009 the Company and its subsidiaries have approximately $4.94 million in cash with approximately $11.8 million in accounts receivables. The majority of these accounts receivables are cycling longer than terms but at anticipated rates. At this time, the Company has no current concern about doubtful accounts.

Financing Initiatives

In FY2008 AMDL worked diligently to attract additional capital with limited success, primarily due to the less than attractive US and China capital and banking markets. With significant and consistent revenue growth in FY2008 and a solid platform for success already underway for FY2009, the Company expects to secure financing of up to US$12-16 million in additional working capital to strengthen AMDL's financial position and meet the Company's 12-18 month funding requirements. Continued financing efforts include the closing of the 2nd tranche of its current unsecured note private placement offering, seeking an institutional investor for a convertible preferred equity transaction, and attempting to establish various US and/or China-based credit facilities.

Going Concern Qualification

On April 15, 2009, AMDL filed with the SEC an Annual Report on Form 10-K in which included an audit opinion with a "going concern" explanatory paragraph which expresses doubt, based upon current financial resources, as to whether AMDL can continue to meet its obligations beyond FY2009 without access to additional working capital. The Company intends to raise additional capital and pursue expense reductions to ensure its ongoing financial viability. This disclosure is in compliance with the NYSE Alternext US Company Guide Rule 610(b) requiring a public announcement of the recei
'/>"/>

SOURCE AMDL, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine news :

1. AMDL, Inc. Selected as #1 Small-Cap Stock Pick for 2009
2. Rudd Report Gives AMDL, Inc. a Strong Buy Recommendation in Year-End Financial Research Report
3. AMDL, Inc. Completes Revision of Performance & Equity Incentive Compensation Plan
4. AMDL, Inc. Chairman & CEO Announces Expert Opinion on Chinas Economic Forecast
5. AMDL, Inc. Announces Final Closing of Private Placement of Senior Notes
6. AMDL, Inc. Issues Correction to January 30, 2009 Press Release Announcing Closing of Private Placement of Senior Notes
7. AMDL, Inc. to Present at 5th Annual Winter Technology Conference Hosted by Security Research Associates, Inc.
8. AMDL, Inc. Reports 2008 Year End Financial Results and Fiscal Year 2009 Financial Targets
9. AMDL, Inc. Enters Into Distribution Agreements With GenWay Biotech, Inc. to Advance Commercialization of the DR-70 (FDP) Cancer Test in the US and Canada
10. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
11. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:U.S. Cancer Cases, Deaths Continue to Drop 2Health News:U.S. Cancer Cases, Deaths Continue to Drop 3Health News:U.S. Cancer Cases, Deaths Continue to Drop 4Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 2Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 3Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 4Health News:Roche Announces Shipments of New Supplies of Children's Tamiflu in the U.S. 5Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 2Health News:Orion Health Participates in International Forum to Break Down Barriers for Health Information Exchange 3Health News:Genetic variations indicate risk of recurrence, secondary cancer among head and neck cancer patients 2Health News:Anthem Blue Cross and Blue Shield in Maine and National Council on Aging Provide Vital Benefits Information to Economically Challenged Older Adults 2
Breaking Medicine Technology:Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 2Despite Limited Capital Equipment Purchases In 2009, The Global Powered Surgical Instrument Market Held Its Value At $800 Million 3Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 2Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 3Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 4Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 5Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 6Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology 7EntreMed Reports Second Quarter 2009 Financial Results 53818 1EntreMed Reports Second Quarter 2009 Financial Results 53818 2EntreMed Reports Second Quarter 2009 Financial Results 53818 3EntreMed Reports Second Quarter 2009 Financial Results 53818 4SXC Health solutions announces record second quarter financial results 53815 1SXC Health solutions announces record second quarter financial results 53815 2SXC Health solutions announces record second quarter financial results 53815 3SXC Health solutions announces record second quarter financial results 53815 4SXC Health solutions announces record second quarter financial results 53815 5SXC Health solutions announces record second quarter financial results 53815 6SXC Health solutions announces record second quarter financial results 53815 7SXC Health solutions announces record second quarter financial results 53815 8SXC Health solutions announces record second quarter financial results 53815 9SXC Health solutions announces record second quarter financial results 53815 10SXC Health solutions announces record second quarter financial results 53815 11SXC Health solutions announces record second quarter financial results 53815 12SXC Health solutions announces record second quarter financial results 53815 13SXC Health solutions announces record second quarter financial results 53815 14SXC Health solutions announces record second quarter financial results 53815 15SXC Health solutions announces record second quarter financial results 53815 16SXC Health solutions announces record second quarter financial results 53815 17SXC Health solutions announces record second quarter financial results 53815 18SXC Health solutions announces record second quarter financial results 53815 19Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 1Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 2Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 3Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 4Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 5Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 6Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 7Stereotaxis Reports 19 25 Second Quarter Revenue Growth 53810 8